Treatment as Prevention¨

PrEP Is Not Magic-and Treating It That Way Undermines Its Incredible Power

It’s been a confusing week with regard to PrEP-an HIV-prevention strategy which currently consists of taking a daily pill (Truvada) to prevent infection if one is exposed to the virus. At a major conference for HIV research-the Conference on Retroviruses and Opportunistic Infections-the CDC revealed that, if deployed widely alongside pushes for more HIV testing

PrEP Is Not Magic-and Treating It That Way Undermines Its Incredible Power Read More »

Botswana close to reaching the 90-90-90 testing and treatment targets

Botswana is already close to reaching the 90-90-90 target for testing, treatment and viral suppression, and is ahead of the United States and most European countries in its efforts to improve treatment coverage, Tendani Gaolathe of the Botswana-Harvard AIDS Institute Partnership reported at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston on

Botswana close to reaching the 90-90-90 testing and treatment targets Read More »

TREMENDOUS PROGRESS MADE IN HIV, BUT SERIOUS DISPARITIES REMAIN

This week, I’m in Boston for the annual Conference on Retroviruses and Opportunistic Infections (CROI). It’s one of the premier scientific meetings where we hear the latest research in HIV prevention and treatment. Last year, for example, researchers presented undeniable evidence that pre-exposure prophylaxis (PrEP) is effective in preventing HIV infection in real-world settings. These

TREMENDOUS PROGRESS MADE IN HIV, BUT SERIOUS DISPARITIES REMAIN Read More »

Advances made in HIV/Aids fight

Treatment has transformed the outlook for people living with HIV from almost certain death to a manageable chronic condition. From our current perspective, it is easy to forget that at the beginning of the Aids pandemic, scientists did not even know the identity of the infectious agent causing a rare immunodeficiency. Rapid scientific advancement was

Advances made in HIV/Aids fight Read More »

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below